DJDanna Jennings

Danna Jennings

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Danna Jennings has a total of 19 co-authors. Here are the top co-authors by number of shared publications:

  • David Oakes

    From the Institute for Neurodegenerative Disorders (D.J., J.S., K.M.), New Haven, CT; Parkinson's Disease and Movement Disorders Center (M.S.), Department of Neurology, University of Pennsylvania, Philadelphia; Department of Biostatistics and Computational Biology (S.E., D.O.), University of Rochester, NY; and Avid Radiopharmaceuticals (A.S.), Philadelphia, PA

    2 shared publications
  • John Seibyl

    From the Institute for Neurodegenerative Disorders (D.J., J.S., K.M.), New Haven, CT; Banner Sun Health Research Institute (M.S.), Sun City, AZ; McLean Hospital (F.L.), Belmont, MA; University of Vermont College of Medicine (W.H.), Burlington, VT; Piramal Imaging GmbH (S.B., A.S., A.M.C.), Berlin, Germany; MRI Research Unit (M.G.), Hospital del Mar, Barcelona, Spain; Navidea Biopharmaceuticals (C.R.) (formerly at Bayer Healthcare); and Bayer Healthcare (B.P.), Berlin, Germany

    2 shared publications
  • Ken Marek

    From the Institute for Neurodegenerative Disorders (D.J., J.S., K.M.), New Haven, CT; Banner Sun Health Research Institute (M.S.), Sun City, AZ; McLean Hospital (F.L.), Belmont, MA; University of Vermont College of Medicine (W.H.), Burlington, VT; Piramal Imaging GmbH (S.B., A.S., A.M.C.), Berlin, Germany; MRI Research Unit (M.G.), Hospital del Mar, Barcelona, Spain; Navidea Biopharmaceuticals (C.R.) (formerly at Bayer Healthcare); and Bayer Healthcare (B.P.), Berlin, Germany

    2 shared publications
  • Shirley Eberly

    From the Institute for Neurodegenerative Disorders (D.J., J.S., K.M.), New Haven, CT; Parkinson's Disease and Movement Disorders Center (M.S.), Department of Neurology, University of Pennsylvania, Philadelphia; Department of Biostatistics and Computational Biology (S.E., D.O.), University of Rochester, NY; and Avid Radiopharmaceuticals (A.S.), Philadelphia, PA

    2 shared publications
  • Ana M. Catafau

    From the Institute for Neurodegenerative Disorders (D.J., J.S., K.M.), New Haven, CT; Banner Sun Health Research Institute (M.S.), Sun City, AZ; McLean Hospital (F.L.), Belmont, MA; University of Vermont College of Medicine (W.H.), Burlington, VT; Piramal Imaging GmbH (S.B., A.S., A.M.C.), Berlin, Germany; MRI Research Unit (M.G.), Hospital del Mar, Barcelona, Spain; Navidea Biopharmaceuticals (C.R.) (formerly at Bayer Healthcare); and Bayer Healthcare (B.P.), Berlin, Germany

    1 shared publication
  • Andrew Siderowf

    From the Institute for Neurodegenerative Disorders (D.J., J.S., K.M.), New Haven, CT; Parkinson's Disease and Movement Disorders Center (M.S.), Department of Neurology, University of Pennsylvania, Philadelphia; Department of Biostatistics and Computational Biology (S.E., D.O.), University of Rochester, NY; and Avid Radiopharmaceuticals (A.S.), Philadelphia, PA

    1 shared publication

Latest Publications

  • Age dependence of brain β-amyloid deposition in Down syndrome

    by Danna Jennings, John Seibyl, Marwan Sabbagh, Florence Lai, William Hopkins, Santi Bullich, Monica Gimenez, Cornelia Reininger, Barbara Putz, Andrew Stephens, et al.

    Objective: To investigate brain β-amyloid binding in subjects with Down syndrome (DS) using [18F]florbetaben PET imaging. Methods: Thirty-nine subjects with DS (46.3 ± 4.7 years) were assessed with [18F]florbetaben PET imaging. Three blinded independent readers assessed the scans to provide a visual analysis. The primary quantitative imaging outcome was a standardized uptake value ratio (SUVR) obtained for 6 brain regions. Cognitive status was evaluated using the Dementia Screening Questionnaire for Individuals with Intellectual Disabilities (DSQIID). Results: [18F]Florbetaben uptake was correlated with age (p < 0.0001, R2 = 0.39); 90% of scans in subjects with DS aged 50 years or older (SUVR = 1.62 ± 0.26), 53% in those aged 45 to 49 years (SUVR = 1.43 ± 0.16), and 7% in those aged 40 to 45 years (SUVR = 1.27 ± 0.11) were visually assessed as positive. Visual and quantitative assessments were highly related (χ2 = 11.3823, p = 0.0007; Cohen κ = 0.58). Only 2 of 34 participants were considered to have dementia by the DSQIID. Conclusions: Brain β-amyloid binding, as measured by [18F]florbetaben, increases with age in DS. Subjects with DS who have no evidence of dementia demonstrate brain β-amyloid binding in vivo, suggesting that [18F]florbetaben PET imaging may detect β-amyloid in this at-risk population.


  • Imaging prodromal Parkinson disease

    by Danna Jennings, Andrew Siderowf, Matthew Stern, John Seibyl, Shirley Eberly, David Oakes, Kenneth Marek, For the PARS Investigators

    Objectives: The purpose of this study is to evaluate the relative risk of abnormal dopamine transporter (DAT) imaging for subjects with and without hyposmia and the feasibility of acquiring a large, community-based, 2-tiered biomarker assessment strategy to detect prodromal Parkinson disease (PD). Methods: In this observational study, individuals without a diagnosis of PD, recruited through 16 movement disorder clinics, underwent tier 1 assessments (olfactory testing, questionnaires). Tier 2 assessments (neurologic examination, DAT imaging, and other biomarker assessments) were completed by 303 subjects. The main outcome of the study is to compare age-expected [123I]β-CIT striatal binding ratio in hyposmic and normosmic subjects. Results: Tier 1 assessments were mailed to 9,398 eligible subjects and returned by 4,999; 669 were hyposmic. Three hundred three subjects (203 hyposmic, 100 normosmic) completed baseline evaluations. DAT deficit was present in 11% of hyposmic subjects compared with 1% of normosmic subjects. Multiple logistic regression demonstrates hyposmia (odds ratio [OR] 12.4; 95% confidence interval [CI] 1.6, 96.1), male sex (OR 5.5; 95% CI 1.7, 17.2), and constipation (OR 4.3; 95% CI 1.6, 11.6) as factors predictive of DAT deficit. Combining multiple factors (hyposmia, male sex, and constipation) increased the percentage of subjects with a DAT deficit to >40%. Conclusion: Subjects with DAT deficit who do not meet criteria for a diagnosis of PD can be identified by olfactory testing. Sequential biomarker assessment may identify those at risk of PD. Selecting hyposmic individuals enriches the population for DAT deficit, and combining hyposmia with other potential risk factors (male sex, constipation) increases the percentage of subjects with a DAT deficit compatible with prodromal PD.


  • Open Access

    (123I) β-CIT and Single-Photon Emission Computed Tomographic Imaging vs Clinical Evaluation in Parkinsonian Syndrome

    by Danna L. Jennings, John P. Seibyl, David Oakes, Shirley Eberly, John Murphy, Ken Marek

    The diagnoses of parkinsonian syndrome (PS) and Parkinson disease (PD) are currently based on clinical evaluation. The most widely accepted clinical definition of PD requires the presence of 2 of 3 cardinal motor signs (tremor, rigidity, and bradykinesia) and a response to levodopa.1 Long-term clinicopathologic studies evaluating the diagnostic accuracy of PD demonstrate that the diagnoses most commonly mistaken for PD are progressive supranuclear palsy and multiple system atrophy.2-4 However, early in its course, the diagnoses most commonly mistaken for PD include essential tremor, vascular parkinsonism, drug-induced parkinsonism, and Alzheimer disease.5,6 In addition, subtle parkinsonian symptoms are relatively common in elderly subjects making the diagnosis especially challenging.7 Retrospective studies have shown that up to 29% of patients initially diagnosed with PS by primary physicians are misdiagnosed.8